Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer, Cancer, Gastrointestinal |
| Therapuetic Areas: | Gastroenterology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/6/2019 |
| Start Date: | March 2011 |
| End Date: | September 2019 |
| Contact: | Prasad Adusumilli, MD |
| Phone: | 212-639-8093 |
A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)
The purpose of this study is to find out whether a protein, called mesothelin, found in the
blood and tissue can be used as "marker" for esophageal cancer. Doctors at Memorial
Sloan-Kettering Cancer Center would like to compare levels of this protein in patients with
abnormal cells or tissue of the esophageal to the levels of this protein in patients being
treated for cancer for the esophagus.
blood and tissue can be used as "marker" for esophageal cancer. Doctors at Memorial
Sloan-Kettering Cancer Center would like to compare levels of this protein in patients with
abnormal cells or tissue of the esophageal to the levels of this protein in patients being
treated for cancer for the esophagus.
Inclusion Criteria:
- Patients with T1 adenocarcinoma or suspected adenocarcinoma who are scheduled for a
biopsy and mucosal resection (Group 1)
- Patients with a T1-2N0 adenocarcinoma or suspected adenocarcinoma who are scheduled to
undergo and esophagectomy (Group 2)
- Patients with T2N1 and T3N0-1 adenocarcinoma or suspected adenocarcinoma who are
scheduled to undergo endoscopy and biopsy and/or endoscopic ultrasound and biopsy
prior to pre-operative chemo-radiotherapy and have baseline and surgical tissue
available for staining (Group 3)
Exclusion Criteria:
- Patients <18 years of age
- Patients unfit medically for endoscopy surveillance and therapy
- Patients unfit medically for esophagectomy
- Patients with stage IV esophageal adenocarcinoma
- Patients previously treated with chemo-radiotherapy for their esophageal cancer
- Patients with squamous cell carcinoma of the esophagus
- Patients who have a history of cancer within 3 years or have a concurrent cancer.
We found this trial at
1
site
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Principal Investigator: Prasad Adusumilli, MD
Phone: 212-639-8093
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
